Bendamustine Hydrochloride
"Bendamustine Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA.
| Descriptor ID |
D000069461
|
| MeSH Number(s) |
D02.241.081.114.625 D02.455.526.728.650.103 D03.633.100.103.123
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bendamustine Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Bendamustine Hydrochloride".
This graph shows the total number of publications written about "Bendamustine Hydrochloride" by people in this website by year, and whether "Bendamustine Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 4 | 4 |
| 2015 | 1 | 3 | 4 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bendamustine Hydrochloride" by people in Profiles.
-
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma. Blood Adv. 2023 11 28; 7(22):7141-7150.
-
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab. Br J Haematol. 2024 01; 204(1):160-170.
-
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-na?ve patients. Semin Hematol. 2023 03; 60(2):73-79.
-
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023 05 10; 41(14):2594-2606.
-
Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial. Blood Cancer J. 2022 11 29; 12(11):162.
-
Treatment of Mantle-Cell Lymphoma. Reply. N Engl J Med. 2022 09 22; 387(12):1148.
-
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 06 30; 386(26):2482-2494.
-
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. Blood Adv. 2022 05 10; 6(9):2757-2762.
-
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044.
-
SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr?m Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556.